Polycystic ovary syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: For 8 weeks, daily intake of one capsule containing two strains of probiotics (Lactobacillus helveticus with a dose of 109 x 3 and Bifidobacterium longum with a dos
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
14 Years to 55 Years
Inclusion criteria
Inclusion criteria: - Patients who agree to participate in the study. - Diagnosis of polycystic ovary syndrome by obstetrician and gynecologist according to the Rotterdam criteria
Exclusion criteria
Exclusion criteria: - Pregnancy and breastfeeding - Consumption of probiotic supplements or products during the last four weeks - Suffering from mental illnesses (major depression, bipolar disorder, and schizophrenia) based on the patient's statement or history of hospitalization in a mental hospital or history of taking psychoactive drugs - Hyperprolactinemia Menopause Uncontrolled diabetes(according to glycosylated hemoglobin index, 8% = HbA1C) Suffering from chronic diseases such as cardiovascular, liver, kidney, neoplasm Performing laparoscopic surgery of ovaries and assisted reproduction technology
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The mean level of fasting blood sugar (FBS) among the intervention and control groups. Timepoint: Before and after intervention. Method of measurement: Fasting blood sample (10 cc of venous blood).;The average level of total cholesterol (HDL, LDL, TG) in the intervention and control groups. Timepoint: before and after intervention. Method of measurement: Fasting blood sample (10 cc of venous blood).;The mean serum level of CRP among intervention and control groups. Timepoint: Before and after intervention. Method of measurement: Fasting blood sample (10 cc of venous blood).;The mean serum level of malondialdehyde (MDA) among intervention and control groups. Timepoint: before and after intervention. Method of measurement: Fasting blood sample (10 cc of venous blood).;The mean level of total antioxidant capacity (TAC) among intervention and control groups. Timepoint: Before and after intervention. Method of measurement: Fasting blood sample (10 cc of venous blood).;The average serum level of superoxide dismutase enzyme (SOD) among intervention and control groups. Timepoint: before and after intervention. Method of measurement: Fasting blood sample (10 cc of venous blood).;The mean serum level of fasting insulin (Insulin) among the intervention and control groups. Timepoint: before and after intervention. Method of measurement: Fasting blood sample (10 cc of venous blood).;The mean serum total testosterone level among the intervention and control groups. Timepoint: Before and after intervention. Method of measurement: Fasting blood sample (10 cc of venous blood).;The mean serum level of sex hormone-binding globulin (SHBG) among the intervention and control groups. Timepoint: Before and after intervention. Method of measurement: Fasting blood sample (10 cc of venous blood).;The average score of mental health indicators (stress, anxiety and depression) among the intervention and control groups. Timepoint: Before and after the intervention. Method of measurement: DASS-21 | — |
Secondary
| Measure | Time frame |
|---|---|
| The mean of quicki index (insulin sensitivity) among intervention and control groups. Timepoint: Before and after intervention. Method of measurement: QUICKI = 1/[log(I0) + log(G0)].;The mean of HOMA-IR index (insulin resistance index) among intervention and control groups. Timepoint: Before and after intervrntion. Method of measurement: HOMA-IR = [) fasting insulin) µU/ml (× fasting glucose) mmo/l ((]/22.5.;The mean of FAI index (free androgen index) among intervention and control groups. Timepoint: Before and after intervention. Method of measurement: FAI = 100 × (Total Testosterone) /SHBG.;Severity of alopecia among intervention and control groups. Timepoint: Before and after intervention. Method of measurement: Alopecia evaluation questionnaire.;Acne severity among intervention and control groups. Timepoint: Before and after intervention. Method of measurement: Acne evaluation questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGholamreza Askari
Esfahan University of Medical Sciences
Outcome results
None listed